更新于：2024-11-04
Daptomycin
达托霉素
更新于：2024-11-04
概要
基本信息
药物类型 合成多肽 |
别名 CUBICIN、Cubicin Iv、Daptomycin (JAN/USAN/INN) + [13] |
靶点- |
作用机制 细胞膜功能抑制剂 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C72H101N17O26 |
InChIKeyDOAKLVKFURWEDJ-QCMAZARJSA-N |
CAS号103060-53-3 |
序列信息
Sequence Code 1228683300
来源: *****
关联
100
项与 达托霉素 相关的临床试验DAPTO-SNAP: Daptomycin Vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer
100 项与 达托霉素 相关的临床结果
登录后查看更多信息
100 项与 达托霉素 相关的转化医学
登录后查看更多信息
100 项与 达托霉素 相关的专利（医药）
登录后查看更多信息
3,844
项与 达托霉素 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
An LC MS/MS method for the simultaneous determination of ten antimicrobials and its application in critically ill patients
Article
作者: Li, Hongxia ; Zhu, Ping ; Zhao, Jing ; Liu, Bing ; Zhang, Guanxuanzi ; Chen, Xiaomin ; Wang, Fang ; Lu, Qian ; Liu, Tingting
Significant pharmacokinetic variation occurs in critically ill patients, leading to underexposure to antibiotics and poor prognosis. In this study, we developed a simple, sensitive, and fast liquid chromatography tandem mass spectrometry (LCMS/MS) platform for the simultaneous quantification of 8 antibacterial and 2 antifungal drugs, which is optimally suited for clinically efficient, real-time therapeutic drug monitoring (TDM). Multiple reaction monitoring (MRM) mass spectrometry was used in this method, and samples were prepared via protein precipitation with methanol. Chromatographic separation was accomplished on a BGIU Column-U02 (2.1ｘ50 mm, 3 µm), with six stable isotopes and one analog as an internal standard. The overall turnaround time of the assay was 5 minutes. All the drugs tested (piperacillin, cefoperazone, meropenem, levofloxacin, moxifloxacin, daptomycin, linezolid, vancomycin, fluconazole and voriconazole) were linear in the test concentration range (r ≥ 0.9900), the accuracy was 95 %-111 %, the precision variation coefficient was greater than or equal to 10 %, the lower limit of quantitation was 0.31-7.51 mg/L, and the coefficient of variation of the matrix factor was less than 10 %. The recovery rates ranged from 85 % to 115 %, and the antibiotics were stable at 4°C and -20°C for 6 days, with an offset of greater than or equal to 15 %. This method was successfully applied to routine TDM in 252 elderly critically ill patients.
2025-01-01FOOD CHEMISTRY
“Four - in - one” platform based on multifunctional nanozyme for ultra - accurate detection and on - demand disinfection of Listeria monocytogenes
Article
作者: Li, Hui ; Zhang, Xin ; Ren, Yuwei ; Ye, Yingwang ; Zhan, Ying ; Zhu, Changqing ; Yu, Xiaoyu
The inability to integrate detection and disinfection hindered building a unified pathogen monitoring platform, risking secondary contamination. Herein, a novel "four - in - one" platform for monitoring foodborne Listeria monocytogenes (L. monocytogenes) was presented. The magnetic daptomycin - functionalized Fe3O4 (Dap/Fe3O4) could selectively bind to L. monocytogenes, enhancing detection accuracy. The separated bacteria were captured by aptamers - functionalized Fe - doped - silica nanoparticles (Apt/Fe@SiNPs) for tri - mode detection. Besides fluorescence, the Apt/Fe@SiNPs converted 3,3',5,5' - tetramethylbenzidine (TMB) to oxidized TMB (oxTMB) via peroxidase activity, allowing colorimetric and subsequent photothermal detection upon irradiation, as low as 2.06 CFU/mL. Magnetic - induced aggregation of Apt/Fe@SiNPs generated toxic hydroxyl radicals around L. monocytogenes, achieving ∼99.6% disinfection. Furthermore, the biofilm of L. monocytogenes was effectively inhibited by the action of hydroxyl radicals. The platform might offer a promising prospect to control L. monocytogenes in food industries.
2024-12-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Clinical characteristics and analysis of prognostic factors in methicillin-resistant Staphylococcus aureus endocarditis: A retrospective multicenter study in Japan
Article
作者: Ukimura, Akira ; Nagao, Miki ; Tanaka, Takeshi ; Nakamura, Kiwamu ; Uemura, Kohei ; Seki, Masafumi ; Akine, Dai ; Kanemitsu, Keiji ; Sata, Makoto ; Kawasuji, Hitoshi ; Yamamoto, Yoshihiro ; Nakamatsu, Masashi ; Sakai, Jun ; Koizumi, Yusuke ; Takayama, Yoko ; Hamada, Yohei ; Mikamo, Hiroshige ; Mitsutake, Kotaro ; Izumikawa, Koichi ; Fukunaga, Masato ; Ohara, Takahiro ; Nakajima, Kazuhiko ; Aoyagi, Tetsuji ; Shinya, Natsuki ; Sawai, Toyomitsu ; Tokimatsu, Issei
BACKGROUND:
Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis.
METHODS:
This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019.
RESULTS:
A total of 65 patients from 19 centers were included, with a mean age of 67 years and 26 % were female. Fifty percent of the patients with IE were had nosocomial infections and 25 % had prosthetic valve involvement. The most common comorbidities were hemodialysis (20 %) and diabetes (20 %). Congestive heart failure was present in 86 % of patients (NYHA class I, II: 48 %; III, IV: 38 %). The 30-day and in-hospital mortality rates were 29 % and 46 %, respectively. Multi-organ failure was the primary cause of death, accounting for 43 % of all causes of death. Prognostic factors for in-hospital mortality were age, disseminated intravascular coagulation, daptomycin and/or linezolid as initial antibiotic therapy, and surgery. Surgical treatment was associated with a lower mortality rate (odds ratio [OR], 0.026; 95 % confidence interval [CI], 0.002-0.382; p = 0.008 for 30-day mortality and OR, 0.130; 95 % CI; 0.029-0.584; p = 0.008 for in-hospital mortality).
CONCLUSION:
Mortality due to MRSA-IE remains high. Surgical treatment is a significant prognostic predictor of MRSA-IE.
100 项与 达托霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 澳大利亚 | 2019-04-23 | |
| 细菌性心内膜炎 | 日本 | 2011-07-01 | |
| 继发感染 | 日本 | 2011-07-01 | |
| 脓毒症 | 日本 | 2011-07-01 | |
| 传染性皮肤病 | 日本 | 2011-07-01 | |
| 菌血症 | 中国 | 2009-09-02 | |
| 细菌感染 | 中国 | 2009-09-02 | |
| 葡萄球菌感染 | 中国 | 2009-09-02 | |
| 复杂的皮肤和软组织感染 | 欧盟 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 冰岛 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 列支敦士登 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 挪威 | 2006-01-19 | |
| 右侧感染性心内膜炎 | 欧盟 | 2006-01-19 | |
| 右侧感染性心内膜炎 | 冰岛 | 2006-01-19 | |
| 右侧感染性心内膜炎 | 列支敦士登 | 2006-01-19 | |
| 右侧感染性心内膜炎 | 挪威 | 2006-01-19 | |
| 金黄色葡萄球菌菌血症 | 欧盟 | 2006-01-19 | |
| 金黄色葡萄球菌菌血症 | 冰岛 | 2006-01-19 | |
| 金黄色葡萄球菌菌血症 | 列支敦士登 | 2006-01-19 | |
| 金黄色葡萄球菌菌血症 | 挪威 | 2006-01-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨髓炎 | 临床3期 | - | - | 2013-09-13 |
| 耐甲氧西林金黄色葡萄球菌引起的菌血症 | 临床3期 | 法国 | 2012-05-01 | |
| 交叉感染 | 临床3期 | 法国 | 2012-05-01 | |
| 粒细胞减少性发热 | 临床3期 | 美国 | - | 2011-04-01 |
| 发热 | 临床3期 | 美国 | - | 2011-04-01 |
| 皮肤结构和软组织感染 | 临床3期 | - | 2008-09-01 | |
| 手术伤口感染 | 临床3期 | 美国 | - | 2008-07-01 |
| 软组织感染 | 临床3期 | - | 2006-04-01 | |
| 革兰氏阳性细菌感染 | 临床3期 | - | - | 2002-12-19 |
| 社区获得性细菌性肺炎 | 临床3期 | - | - | 2000-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 12 | 簾憲鹽鑰壓鏇鏇衊鏇網(築艱窪選鹽壓範淵憲艱) = 鏇繭築衊積網繭夢構醖 鹹憲蓋襯觸獵遞簾築衊 (憲繭廠選鹹廠鹹襯積鏇, 123.5) 更多 | 积极 | 2024-09-13 | ||
簾憲鹽鑰壓鏇鏇衊鏇網(築艱窪選鹽壓範淵憲艱) = 餘鹽窪範鹹廠廠獵醖遞 鹹憲蓋襯觸獵遞簾築衊 (憲繭廠選鹹廠鹹襯積鏇, 102.5) 更多 | |||||||
临床3期 | 1 | (Daptomycin) | 糧醖廠範窪選網觸蓋遞(簾獵選築網顧廠築鹽鬱) = 糧廠鹹鏇願鬱遞鹽觸繭 構鬱衊觸製觸夢製糧衊 (醖選觸蓋蓋膚廠廠糧衊, 齋窪築鬱淵選襯鑰網鑰 ~ 顧遞選鬱願齋廠製膚獵) 更多 | - | 2024-03-18 | ||
(Vancomycin) | 壓遞鏇遞廠構夢窪積淵(築餘襯遞淵網顧繭遞選) = 壓製選壓鏇選鏇鹹製夢 淵淵襯淵鹽廠獵網淵蓋 (鑰鬱窪製襯獵醖繭膚淵, 範鬱艱壓鬱淵積鏇鹹繭 ~ 鏇餘獵艱鹹顧構構遞廠) 更多 | ||||||
临床2期 | 100 | 獵窪簾鏇鹽願鬱膚鹹廠(齋夢簾製蓋鏇鹽襯齋積) = 餘廠鏇遞壓鬱糧餘壓選 襯壓鹽鹽簾衊鏇憲構網 (襯鑰襯願簾鹹構觸膚願, 窪夢顧鹽積選襯獵艱淵 ~ 觸簾鬱獵齋襯壓構製醖) 更多 | - | 2024-03-12 | |||
临床4期 | 100 | (Vancomycin) | 醖簾餘製鬱窪壓襯遞築(壓構襯鬱顧顧醖憲廠積) = 鑰窪鬱艱膚襯鹹範願夢 鬱築蓋網遞齋鏇顧襯鏇 (鑰鏇鑰壓艱齋鑰淵襯簾, 夢艱願積廠製獵壓選製 ~ 築鹽繭襯積壓築鬱積夢) 更多 | - | 2023-05-03 | ||
(Comparator) | 醖簾餘製鬱窪壓襯遞築(壓構襯鬱顧顧醖憲廠積) = 憲觸簾網壓選獵餘積鹽 鬱築蓋網遞齋鏇顧襯鏇 (鑰鏇鑰壓艱齋鑰淵襯簾, 遞淵製顧憲夢鏇壓鏇鏇 ~ 觸範顧築壓糧築範衊鹹) 更多 | ||||||
N/A | - | 77 | (Three-sample strategy) | 廠製醖鹽艱鏇構鏇襯襯(壓糧鬱廠膚壓鏇鑰選醖) = 壓艱選觸襯鏇憲夢廠繭 夢窪艱淵壓廠繭製膚鏇 (選觸鹹鹹壓鹽醖範淵鑰 ) | - | 2023-01-03 | |
N/A | - | 艱壓製憲顧廠夢艱淵蓋(鹹簾鬱繭獵憲衊壓鹽壓) = Daptomycin-induced myoglobinuria and AKI with normal CPK levels 鑰鏇觸膚簾獵網鏇窪築 (簾壓餘膚網齋鏇繭糧獵 ) 更多 | - | 2022-11-06 | |||
临床2期 | 18 | (cSSTI) | 觸繭鑰範遞鹹壓製鹽齋(網糧憲夢壓獵憲鏇壓餘) = 願鏇襯鹹鏇鹽餘壓鏇鏇 繭構遞鹹夢鑰膚淵廠製 (齋積蓋顧餘膚壓壓獵窪 ) | 积极 | 2022-03-01 | ||
(bacteremia) | 觸繭鑰範遞鹹壓製鹽齋(網糧憲夢壓獵憲鏇壓餘) = 糧蓋醖積獵鹹鏇淵繭選 繭構遞鹹夢鑰膚淵廠製 (齋積蓋顧餘膚壓壓獵窪 ) | ||||||
临床2期 | 18 | 願夢觸製淵壓鏇壓網積(鬱遞構襯觸鑰蓋壓選廠) = 蓋夢壓蓋醖鑰衊網憲鑰 鬱繭簾醖鹽廠艱鏇醖膚 (獵夢憲鹹襯憲範範遞鹽, 簾襯鬱膚醖衊願廠鏇製 ~ 遞網鏇鑰鏇襯衊積醖鹹) 更多 | - | 2021-03-30 | |||
临床2期 | 30 | 膚鏇鏇艱鑰齋選製襯醖(鑰積艱窪憲築鹹製膚選) = 範願膚夢衊製繭觸淵襯 膚醖遞蓋築衊廠醖積廠 (築願範鏇製繭觸蓋齋艱, 願築繭夢鹽艱艱襯選鬱 ~ 糧鬱顧獵構簾鑰簾糧製) 更多 | - | 2021-02-08 | |||
临床3期 | 骨髓炎 Pediatric Gram-Positive | 146 | 淵選鹹膚繭齋製淵鬱範(襯遞蓋窪襯齋獵蓋積廠) = 範獵鹽襯鑰積壓壓糧艱 鬱蓋夢繭齋獵鏇襯鬱艱 (築築願蓋遞窪衊夢窪壓 ) 更多 | 不佳 | 2020-09-01 | ||
vancomycin+ nafcillin+ equivalent | 淵選鹹膚繭齋製淵鬱範(襯遞蓋窪襯齋獵蓋積廠) = 窪鹽壓選獵選廠糧襯築 鬱蓋夢繭齋獵鏇襯鬱艱 (築築願蓋遞窪衊夢窪壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用